Top Markets
Coin of the day
CompuGroup Medical SE & Co. KGaA CompuGroup Medical SE & Co. KGaA

CompuGroup Medical SE & Co. KGaA

COP
Rank in Stocks #7996
CompuGroup Medical SE & Co. KGaA (CGM) is a global developer and vendor of... CompuGroup Medical SE & Co. KGaA (CGM) is a global developer and vendor of sophisticated information technology and software solutions tailored for the healthcare industry. The company organizes its diverse offerings into four primary operational segments: Ambulatory Information Systems (AIS): This segment furnishes physicians, medical centers, and professional networks with essential practice management software and electronic medical records. It also provides complementary internet and intranet-based tools to support outpatient care. Pharmacy Information Systems (PCS): Focusing on the pharmaceutical sector, PCS delivers administrative and billing software applications designed for pharmacies. These solutions offer critical information and decision-making support for managing the intricate medication supply chain. Hospital Information Systems (HIS): Catering to the inpatient environment, this segment provides comprehensive clinical and administrative solutions. Its clientele includes acute care hospitals, rehabilitation facilities, social service organizations, multi-site hospital networks, regional care providers, and medical laboratories. Consumer & Health Management Information Systems (CHS): This broad segment encompasses services such as IT security, data-driven product suites, interfaces for information exchange, clinical decision support tools, and extensive medication and treatment databases for healthcare service providers. Additionally, it develops digital healthcare platforms, consumer portals, and mobile applications, along with security measures for providers. Its customer base is expansive, covering pharmaceutical companies, health insurance providers, other healthcare IT firms, and direct consumers. Founded in 1987 and headquartered in Koblenz, Germany, the company officially adopted its current designation, CompuGroup Medical SE & Co. KGaA, in June 2020, having previously operated as CompuGroup Medical SE.
Share Price
$26.88
Last synced: 2025-06-24
Market Cap
$1.39B
Change (1 day)
3.42%
Change (1 year)
0.00%
Country
DE
Trade CompuGroup Medical SE & Co. KGaA (COP)

Category

P/E ratio for CompuGroup Medical SE & Co. KGaA (COP)
P/E ratio as of August 2026 TTM: 33.82
According to CompuGroup Medical SE & Co. KGaA latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.82. At the end of 2023 the company had a P/E ratio of 43.23.
P/E ratio history for CompuGroup Medical SE & Co. KGaA from 2004 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 33.82 3.94%
2024 32.54 -24.74%
2023 43.23 68.86%
2022 25.60 -52.58%
2021 53.98 -6.45%
2020 57.70 23.06%
2019 46.89 124.20%
2018 20.91 -76.82%
2017 90.22 107.43%
2016 43.49 -0.38%
2015 43.66 14.73%
2014 38.05 -4.25%
2013 39.74 66.79%
2012 23.83 -47.20%
2011 45.13 36.25%
2010 33.12 3.20%
2009 32.09 -74.10%
2008 123.91 338.44%
2007 28.26 26.47%
2006 22.35 162.71%
2005 8.51 -35.79%
2004 13.25 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
21.18 -37.39%
US
79.49 135.04%
AU
43.15 27.60%
US
-36.43 -207.73%
US
- -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.